| Outcome | Probability | Yes Bid | Yes Ask | 24h Change | Volume | |
|---|---|---|---|---|---|---|
| Before April 15 | 0% | 0¢ | 0¢ | — | $0 | Resolved |
| Before May | 0% | 0¢ | 0¢ | — | $0 | Resolved |
| Before July | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before September | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before November | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before 2027 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
This market asks when the U.S. Food and Drug Administration will reclassify the investigational peptide BPC-157 into the market-defined 'Category 1.' The outcome matters because such an action would change the regulatory status and could affect research, clinical use, enforcement, and commercial availability.
BPC-157 is a synthetic peptide that has been studied in preclinical models and used in research and some clinical-adjacent settings, but it has not been broadly approved by the FDA through standard drug-approval pathways. Reclassification to 'Category 1' in this market requires a formal FDA action as defined by the event rules; achieving that typically involves regulatory submissions, clinical evidence, or an explicit agency determination. Market participants should consult the event's official resolution language to see exactly which FDA communications or documents qualify as reclassification.
Market prices aggregate traders' views about the timing of an FDA action given public information; treat them as a continuously updated signal of market expectations rather than as a guarantee of outcome. Use those prices alongside independent regulatory, clinical, and sponsor developments when forming your own judgment.
Resolution depends on the event's official rules; generally it requires a formal, verifiable FDA action or public communication that matches the market's defined criteria (for example an approval letter, final rule, or explicit FDA statement). Consult the market's resolution language to see which document types and issuances qualify.
Decisions about drug classification or approval typically involve CDER (Center for Drug Evaluation and Research), the Office of New Drugs, and review divisions; Office of Compliance and the Office of Regulatory Affairs may be involved for enforcement-related reclassification. Final public actions can also reflect input from advisory committees or the FDA leadership team.
Robust human clinical trial data demonstrating an acceptable safety and efficacy profile, well-characterized manufacturing and quality controls (CMC), complete regulatory dossiers or petitions, and transparent postmarketing or safety-monitoring plans are the main drivers of a favorable regulatory change.
Not necessarily—advisory committee votes, draft guidances, or preliminary statements are often informative but may not meet the event's definition of 'reclassification.' Only the specific types of official FDA actions listed in the market's resolution rules will determine the outcome.
Yes: other peptides and biologics that moved from research use to formal FDA authorization show wide variation in timelines, often spanning multiple years. Key determinants in those precedents include quality of clinical evidence, sponsor investment, manufacturing readiness, and regulatory complexity.